Patent Number: 6,169,093

Title: Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Abstract: Compounds of formula I, ##STR1## wherein R.sup.1 represents C.sub.1-4 alkoxy optionally substituted by one or more fluorine atoms; R.sup.2 represents H or C.sub.1-6 alkoxy optionally substituted by one or more fluorine atoms; R.sup.3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted; R.sup.4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula Ia, ##STR2## or represents a chain of formula Ib, ##STR3## and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.

Inventors: Fox; David Nathan Abraham (Sandwich, GB)

Assignee: Pfizer Inc.

International Classification: C07D 405/04 (20060101); C07D 405/00 (20060101); C07D 413/04 (20060101); C07D 413/00 (20060101); C07D 409/04 (20060101); C07D 401/14 (20060101); C07D 471/00 (20060101); C07D 409/00 (20060101); C07D 401/00 (20060101); C07D 401/04 (20060101); C07D 471/04 (20060101); A61K 031/517 (); C07D 239/72 ()

Expiration Date: 01/02/2018